- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04003142
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2 (Skylight 2)
A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, Followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause
This study was for women in menopause with moderate to severe hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life.
The study treatments are fezolinetant 30 mg (1 tablet of fezolinetant and 1 placebo tablet) once a day, fezolinetant 45 mg (2 tablets of fezolinetant) once a day or placebo (2 tablets) once a day. (Placebo is a dummy treatment that looks like medicine but does not have any medicine in it.) The study compared fezolinetant and placebo after 4 and 12 weeks of dosing. The study evaluated if fezolinetant reduces the number of hot flashes and the study evaluated if fezolinetant reduces the severity of the hot flashes.
Women in the study received an electronic handheld device at the first study visit. (It is similar to a smart phone.) Each day of the study, study participants used this to record their hot flashes. Their record for the 10 days before the start of study treatment was checked. They remained in the study if their record shows 7 or 8 moderate to severe hot flashes per day (50 or more per week). Next, they were picked for 1 of the 2 study treatments (fezolinetant or placebo) by chance alone. It is like flipping a coin.
The study participants took study treatment for 52 weeks. The first 12 weeks of study treatment was "double-blinded." That means that the study participants and the study doctors did not know who took which of the study treatments (fezolinetant 30 mg, fezolinetant 45 mg or placebo) during that time. The last 40 weeks of study treatment was "noncontrolled." That means that each study participant and the study doctors knew which study treatment that study participant took during that time. Women who took fezolinetant during the first 12 weeks continued to take the same dose. Women who took placebo during the first 12 weeks took fezolinetant. Their dose was either 30 mg or 45 mg fezolinetant.
At weeks 2, 4, 8, 12, 14, 16 and then once a month, the study participants went to the hospital or clinic for a check-up. They were asked about medications, side effects and how they felt. Other checks included physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine was collected for laboratory tests. Study participants completed questionnaires that were about how hot flashes affect their daily life. Study participants who had their uterus had the following 2 tests done at the first and last study visits. One of the 2 tests was endometrial biopsy. This test involved removing a small amount of tissue from the inside lining of the uterus. The tissue was then checked under a microscope. The other test was transvaginal ultrasound. This test used sound waves to create pictures of the organs in the pelvis. The sound waves are transmitted by a probe (transducer), which was placed inside the vagina. Study participants might have a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not have this test done in the last 12 months had it done at the first study visit. They had done at the last study visit if they were due for their screening mammogram and their own doctor agrees.
The last check-up at the hospital or clinic was 3 weeks after the last dose of study treatment.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada
- Site CA15008
-
-
Ontario
-
Sarnia, Ontario, Canada, N7T 4X3
- Site CA15006
-
Toronto, Ontario, Canada, M3J 2C5
- Site CA15009
-
-
Quebec
-
Levis, Quebec, Canada
- Site CA15007
-
Sherbrooke, Quebec, Canada, J1L 0H8
- Site CA15002
-
Victoriaville, Quebec, Canada, G6P 6P6
- Site CA15001
-
-
-
-
-
Pisek, Czechia, 39701
- Site CZ42007
-
Praha 2, Czechia, 12000
- Site CZ42006
-
Praha 9, Czechia, 190 12
- Site CZ42004
-
Tabor 3, Czechia, 39003
- Site CZ42005
-
Vsetin, Czechia, 75501
- Site CZ42003
-
-
-
-
-
Riga, Latvia, 1005
- Site LV37101
-
Riga, Latvia
- Site LV37103
-
-
-
-
-
Bydgoszcz, Poland, 85-065
- Site PL48001
-
Elblag, Poland, 82-300
- Site PL48013
-
Katowice, Poland, 40-851
- Site PL48009
-
Krakow, Poland
- Site PL48011
-
Lublin, Poland, 20-069
- Site PL48002
-
Lublin, Poland
- Site PL48012
-
Piaseczno, Poland, 05-500
- Site PL48004
-
Poznan, Poland, 60-192
- Site PL48006
-
Szczecin, Poland, 71-434
- Site PL48005
-
Warsaw, Poland, 02-201
- Site PL48010
-
Warszawa, Poland, 02777
- Site PL48003
-
-
-
-
-
Aravaca, Spain, 28023
- Site ES34003
-
Centelles, Spain, 08540
- Site ES34002
-
Madrid, Spain, 28041
- Site ES34001
-
-
-
-
-
Shipley, United Kingdom, BD18 3SA
- Site GB44001
-
-
-
-
Arizona
-
Mesa, Arizona, United States, 85209
- Mesa Obstetricians and Gynecologists
-
Phoenix, Arizona, United States, 85032
- Precision Trials
-
Tucson, Arizona, United States, 85712
- Visions Clinical Research - Tuscon
-
-
California
-
Oceanside, California, United States, 92056
- Excell Research
-
Pomona, California, United States, 91767
- Dream Team Clinical Research, LLC
-
Sacramento, California, United States, 95821
- Clinical Trials Research
-
San Diego, California, United States, 92108
- Wake Research Associates, LLC
-
San Diego, California, United States, 92111
- Women's Healthcare Affiliates
-
Valley Village, California, United States, 91607
- Bayview Research Group
-
-
Colorado
-
Denver, Colorado, United States, 80209
- Downtown Women's Health Care
-
Denver, Colorado, United States, 80220
- Horizons Clincial Research Center LLC
-
Lakewood, Colorado, United States, 80228
- Physicians' Research Options/Red Rocks OB/GYN
-
-
Florida
-
Boynton Beach, Florida, United States, 33436
- Helix Biomedics
-
Cape Coral, Florida, United States, 33991
- Renaissance Research and Medical Group, Inc.
-
Crystal River, Florida, United States, 34429
- Nature Coast Clinical Research
-
Melbourne, Florida, United States, 32940
- Bioclinica Research, Melbourne
-
Miami, Florida, United States, 33126
- LCC Medical Research Institute, LLC
-
Miami, Florida, United States, 33135
- Suncoast Clinical Research, Inc.
-
Miami, Florida, United States, 33176
- Suncoast Research
-
Miami, Florida, United States, 33186
- Medical Health Center & Research
-
North Miami, Florida, United States, 33161
- Healthcare Clinical Data Inc
-
Ocoee, Florida, United States, 34761
- Sensible Healthcare LLC
-
Orlando, Florida, United States, 32806
- Bioclinica Research
-
Ormond Beach, Florida, United States, 32174
- Ormond Medical Arts Pharmaceutical Research Center
-
Port Orange, Florida, United States, 32127
- Progressive Medical Research
-
Saint Petersburg, Florida, United States, 33709
- Meridien Research
-
Sarasota, Florida, United States, 34239-3132
- Physician Care Clinical Research, LLC
-
Tampa, Florida, United States, 33614
- GCP Clinical Research, LLC
-
West Palm Beach, Florida, United States, 33409
- Comprehensive Clinical Development
-
Winter Haven, Florida, United States, 33880
- Clinical Research of Central Florida
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
- Agile Clinical Research Trials, LLC
-
Atlanta, Georgia, United States, 30312-1220
- Georgia Research for Women
-
Decatur, Georgia, United States, 30030
- iResearch Atlanta LLC
-
Sandy Springs, Georgia, United States, 30328
- WR-Mount Vernon Clinical Research
-
Snellville, Georgia, United States, 30078
- Georgia Clinical Research
-
-
Idaho
-
Blackfoot, Idaho, United States, 83221
- Elite Clinical Trials
-
Nampa, Idaho, United States, 83687
- ASR, LLC-Advanced Specialty Research
-
-
Illinois
-
Oak Brook, Illinois, United States, 60523
- Affinity Clinical Research Institute
-
-
Kansas
-
Wichita, Kansas, United States, 67226
- Cypress Medical Research Center
-
-
Louisiana
-
Marrero, Louisiana, United States, 70072
- Praetorian Pharmaceutical Research
-
Metairie, Louisiana, United States, 70001
- Southern Clinical Research Associates
-
New Orleans, Louisiana, United States, 70125
- Women Under Study, LLC
-
-
Maryland
-
Baltimore, Maryland, United States, 21210
- Pharmasite Research Inc
-
-
Nevada
-
Las Vegas, Nevada, United States, 89104-3218
- Clinical Research Center of Nevada (CRCN)
-
Las Vegas, Nevada, United States, 89128
- Dr.R. Garn Mabey, MD,Office Of
-
-
New Jersey
-
Berlin, New Jersey, United States, 08009
- Hassman Research Institute, LLC
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Albuquerque Clinical Trials, Inc.
-
Albuquerque, New Mexico, United States, 87109-4640
- Bosque Women's Care
-
-
New York
-
West Seneca, New York, United States, 14224
- Circuit Clinical
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
- Premier Gynecology & Wellness
-
Greensboro, North Carolina, United States, 27408
- Medication Management, LLC
-
-
Ohio
-
Englewood, Ohio, United States, 45322
- HWC Women's Research Center
-
-
Pennsylvania
-
Erie, Pennsylvania, United States, 16507
- OB/GYN Associates of Erie
-
Jenkintown, Pennsylvania, United States, 19046
- Dr. Marvin Kalafer MD, Office Of
-
Pittsburgh, Pennsylvania, United States, 15243
- Research Protocol Management Specialists
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Clinical Neuroscience Solutions, Inc
-
-
Texas
-
Carrollton, Texas, United States, 75007
- The Clinical Research Center, LLC
-
Houston, Texas, United States, 77058
- Centex Studies, Inc.
-
Houston, Texas, United States, 77030
- Advances In Health
-
Lampasas, Texas, United States, 76550
- FMC Science
-
Plano, Texas, United States, 75024
- ClinRx Research
-
-
Utah
-
Riverton, Utah, United States, 84065
- Granger Medical Clinic
-
Salt Lake City, Utah, United States, 84107
- Wasatch Clinical Research, LLC
-
-
Washington
-
Seattle, Washington, United States, 98115
- Seattle Women's: Health, Research, Gynecology
-
Spokane, Washington, United States, 99207
- North Spokane Women's Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject has a body mass index ≥ 18 kg/m^2 and ≤ 38 kg/m^2.
Subject must be seeking treatment or relief for vasomotor symptoms (VMS) associated with menopause and confirmed as menopausal per 1 of the following criteria at the screening visit:
- Spontaneous amenorrhea for ≥ 12 consecutive months
- Spontaneous amenorrhea for ≥ 6 months with biochemical criteria of menopause (follicle-stimulating hormone [FSH] > 40 IU/L); or
- Having had bilateral oophorectomy ≥ 6 weeks prior to the screening visit.
- Within the 10 days prior to randomization, subject must have a minimum average of 7 to 8 moderate to severe hot flashes (HFs) vasomotor symptoms (VMS) per day, or 50 to 60 per week.
- Subject is in good general health as determined on the basis of medical history and general physical examination, including a bimanual clinical pelvic examination and clinical breast examination devoid of relevant clinical findings, performed at the screening visit; hematology and biochemistry parameters, pulse rate and/or blood pressure and electrocardiogram (ECG) within the reference range for the population studied, or showing no clinically relevant deviations.
- Subject has documentation of a normal/negative or no clinically significant findings mammogram (obtained at screening or within the prior 12 months of study enrollment). Appropriate documentation includes a written report or an electronic report indicating normal/negative or no clinically significant mammographic findings.
- Subject is willing to undergo a transvaginal ultrasound (TVU) to evaluate the uterus and ovaries at screening and at week 52 end of treatment (EOT), and for subjects who are withdrawn from the study prior to completion, a TVU at the early discontinuation (ED) visit.
- Subject is willing to undergo an endometrial biopsy at screening and at week 52 (EOT), for subjects with uterine bleeding, and for subjects who are withdrawn from the study prior to completion. The endometrial biopsy obtained at screening must be considered evaluable.
- Subject has documentation of a normal or not clinically significant Papanicolaou (Pap) test (or equivalent cervical cytology) within the previous 12 months or at screening.
- Subject has a negative urine pregnancy test at screening.
- Subject has a negative serology panel (i.e. negative hepatitis B surface antigen, negative hepatitis C virus antibody and negative human immunodeficiency virus antibody screens) at screening.
- Subject agrees not to participate in another interventional study while participating in the present study.
Exclusion Criteria:
- Subject uses a prohibited therapy (strong or moderate cytochrome P450 1A2 [CYP1A2] inhibitors, hormone replacement therapy [HRT], hormonal contraceptive or any treatment for VMS [prescription, over the counter or herbal]) or is not willing to wash out and discontinue use of such drugs for the full duration of study conduct.
- Subject has known substance abuse or alcohol addiction within 6 months of screening.
- Subject has previous or current history of a malignant tumor, except for basal cell carcinoma.
Subject's systolic blood pressure is ≥ 130 mmHg or diastolic blood pressure is ≥ 80 mmHg based on the average of 2 to 3 readings, on at least 2 different occasions within the screening period.
- Subjects who do not meet these criteria may be re-assessed after initiation or review of antihypertensive measures.
- Subjects with a medical history of hypertension can be enrolled once they are medically clear (stable and compliant).
- Subject has history of severe allergy, hypersensitivity or intolerance to drugs in general, including the study drug and any of its excipients.
- Subject has an unacceptable result from the TVU assessment at screening (i.e., full length of endometrial cavity cannot be visualized or presence of a clinically significant finding).
- Subject has an endometrial biopsy confirming presence of disordered proliferative endometrium, endometrial hyperplasia, endometrial cancer or other clinically significant findings at screening.
- Subject has a history within the last 6 months of undiagnosed uterine bleeding.
- Subject has a history of seizures or other convulsive disorders.
- Subject has a medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], endocrine or gynecological disease) or malignancy that could confound interpretation of the study outcome.
- Subject has active liver disease, jaundice or elevated liver aminotransferases (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]), elevated total or direct bilirubin, elevated international normalized ratio (INR), or elevated alkaline phosphatase (ALP). Patients with mildly elevated ALT or AST up to 1.5 times the upper limit of normal (ULN) can be enrolled if total and direct bilirubin are normal. Patients with mildly elevated ALP (up to 1.5 x ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Patients with Gilbert's syndrome with elevated total bilirubin may be enrolled as long as direct bilirubin, hemoglobin and reticulocytes are normal.
- Subject has creatinine > 1.5 × ULN; or estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula ≤ 59 mL/min per 1.73 m^2 at screening.
- Subject has a history of suicide attempt or suicidal behavior within the last 12 months or has suicidal ideation within the last 12 months (a response of "yes" to question 4 or 5 on the suicidal ideation portion of the Columbia Suicide Severity Rating Scale [C-SSRS]), or who is at significant risk to commit suicide at screening and at randomization.
- Subject has previously been enrolled in a clinical trial with fezolinetant.
- Subject is participating concurrently in another interventional study or participated in an interventional study within 28 days prior to screening, or received any investigational drug within 28 days or within 5 half-lives prior to screening, whichever is longer.
- Subject is unable or unwilling to complete the study procedures.
- Subject has any condition which makes the subject unsuitable for study participation.
- Subject has had partial or full hysterectomy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Double-blind Period: Placebo
Participants received fezolinetant matching placebo (two fezolinetant matching placebo tablets) orally, once daily (QD) up to week 12 during double-blind treatment period.
|
Oral Tablet
|
Experimental: Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg
Participants received fezolinetant 30 mg (one 30 mg fezolinetant tablet and one placebo tablet) orally, QD up to week 12 during double-blind treatment period followed by fezolinetant 30 mg orally, QD from week 13 up to Week 52 during extension treatment period.
|
Oral tablet
|
Experimental: Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg
Participants received fezolinetant 45 mg (one 30 mg tablet and one 15 mg tablet) orally, QD up to week 12 during double-blind treatment period followed by fezolinetant 45 mg orally, QD from week 13 up to Week 52 during extension treatment period.
|
Oral tablet
|
Experimental: Double-blind Period: Placebo/Extension Period: Fezolinetant 30 mg
Participants who received placebo during double-blind treatment period were re-randomized to receive fezolinetant 30 mg orally, QD from week 13 up to week 52 during extension treatment period.
|
Oral tablet
|
Experimental: Double-blind Period: Placebo/Extension Period: Fezolinetant 45 mg
Participants who received placebo during double-blind treatment period were re-randomized to receive fezolinetant 45 mg orally, QD from week 13 up to week 52 during extension treatment period.
|
Oral tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4
Time Frame: Baseline and week 4
|
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours.
A daily frequency per week was derived by taking the mean of the data over 7 days.
Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity.
If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets.
Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity.
If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.
|
Baseline and week 4
|
Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12
Time Frame: Baseline and week 12
|
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours.
A daily frequency per week was derived by taking the mean of the data over 7 days.
Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity.
If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets.
Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity.
If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.
|
Baseline and week 12
|
Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4
Time Frame: Baseline and week 4
|
Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: [(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity. |
Baseline and week 4
|
Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12
Time Frame: Baseline and week 12
|
Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: [(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity. |
Baseline and week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in The Mean Patient-reported Outcomes Measurement Information System Sleep Disturbance - Short Form 8b (PROMIS SD SF 8b) Total Score at Week 12
Time Frame: Baseline and week 12
|
The PROMIS SD SF 8b assesses self-reported sleep disturbance over the past 7 days and includes perceptions of restless sleep; satisfaction with sleep; refreshing sleep; difficulties sleeping, getting to sleep or staying asleep; amount of sleep; and sleep quality.
Because it assesses the participants experience of sleep disturbance, the measure does not focus on specific sleep-disorder symptoms or ask participants to report objective measures of sleep (e.g., total amount of sleep, time to fall asleep and amount of wakefulness during sleep).
Responses to each of the 8 items range from 1 (no disturbed sleep) to 5 (disturbed sleep), and the range of possible summed raw scores is 8 to 40.
Higher scores on the PROMIS SD SF 8b indicate more of the disturbed sleep.
|
Baseline and week 12
|
Change From Baseline in The Mean Frequency of Moderate, and Severe VMS to Each Study Week Up to Week 12
Time Frame: Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10, and 11
|
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours.
A daily frequency per week was derived by taking the mean of the data over 7 days.
Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity.
If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets.
Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity.
If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.
|
Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10, and 11
|
Change From Baseline in The Mean Severity of Moderate, and Severe VMS to Each Study Week Up to Week 12
Time Frame: Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10 and 11
|
Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: [(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity. |
Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10 and 11
|
Mean Percent Change in The Frequency of Moderate And Severe Vasomotor Symptoms From Baseline to Each Study Week Up to Week 12
Time Frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
|
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours.
A daily frequency per week was derived by taking the mean of the data over 7 days.
Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity.
If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets.
Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity.
If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.
|
Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
|
Number of Participants With Percent Reduction of >=50% in the Mean Frequency of Moderate and Severe VMS From Baseline to Each Study Week Up to Week 12
Time Frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
|
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours.
A daily frequency per week was derived by taking the mean of the data over 7 days.
Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity.
If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets.
Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity.
If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.
Participant has >=50% reduction from baseline to each post baseline week for the frequency of moderate to severe VMS.
|
Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
|
Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate, and Severe VMS From Baseline to Each Study Week Up to Week 12
Time Frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
|
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours.
A daily frequency per week was derived by taking the mean of the data over 7 days.
Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity.
If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets.
Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity.
If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.
Participant has 100% reduction from baseline to each post baseline week for the frequency of moderate to severe VMS.
|
Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
|
Change From Baseline in The Mean Frequency of Moderate, and Severe VMS at Week 24
Time Frame: Baseline and 24 weeks of fezolinetant exposure (week 36 for arms Placebo/Fezolinetant 30 mg and Placebo/Fezolinetant 45 mg)
|
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours.
A daily frequency per week was derived by taking the mean of the data over 7 days.
Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity.
If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets.
Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity.
If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.
|
Baseline and 24 weeks of fezolinetant exposure (week 36 for arms Placebo/Fezolinetant 30 mg and Placebo/Fezolinetant 45 mg)
|
Change From Baseline in The Mean Severity of Moderate, and Severe VMS at Week 24
Time Frame: Baseline and 24 weeks of fezolinetant exposure (week 36 for arms Placebo/Fezolinetant 30 mg and Placebo/Fezolinetant 45 mg)
|
Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: [(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity. |
Baseline and 24 weeks of fezolinetant exposure (week 36 for arms Placebo/Fezolinetant 30 mg and Placebo/Fezolinetant 45 mg)
|
Number of Participants in Each Category of Patient's Global Impression of Change (PGIC) in VMS at Each Visit
Time Frame: Weeks 4, 12, 16, 20, 24, 28, 32, 36, 40, 44, 52 of fezolinetant exposure (weeks 16, 24, 28, 32, 36, 40, 44, 48 and 52 for arms Placebo/Fezolinetant 30 mg and Placebo/Fezolinetant 45 mg)
|
The PGI is comprised of 2 companion 1-item PRO measures analogous to the Clinical Global Impression (CGI) scales. These measures provide brief, stand-alone global assessments prior to and after initiating a study medication. Patient-perceived change from the initiation of treatment (PGI-C)-VMS is used to evaluate meaningful within-person changes over time in VMS. This measure provides patient-perceived change from the initiation of treatment. The PGI-C VMS asks: "Compared to the beginning of this study, how would you rate your HFs/night sweats now?" Subject ratings range from (1) much better to (7) much worse. Participant ratings range from 1=much better, 2= moderately better, 3= a little better, 4= no change, 5= a little worse, 6= moderately worse, 7= much worse. |
Weeks 4, 12, 16, 20, 24, 28, 32, 36, 40, 44, 52 of fezolinetant exposure (weeks 16, 24, 28, 32, 36, 40, 44, 48 and 52 for arms Placebo/Fezolinetant 30 mg and Placebo/Fezolinetant 45 mg)
|
Number of Participants With Adverse Events
Time Frame: From first dose date up to 21 days after last dose (up to 55 weeks)
|
An AE is any untoward medical occurrence in a participant administered a study drug, & which does not necessarily have to have a causal relationship with treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with use of a medicinal product (mp) whether or not considered related to the mp.
An AE is considered "serious" if it results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, Results in congenital anomaly or birth defect, requires inpatient hospitalization or leads to prolongation of hospitalization, hospitalization for treatment/observation/examination caused by AE is to be considered as serious, discontinuation due to increases in liver enzymes, other medically important events.
TEAE was defined as an AE observed from first dose date up to 21 days after last dose.
|
From first dose date up to 21 days after last dose (up to 55 weeks)
|
Collaborators and Investigators
Investigators
- Study Director: Executive Medical Director, Astellas Pharma Global Development, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2693-CL-0302
- 2018-003529-27 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hot Flashes
-
Mitsubishi Tanabe Pharma America Inc.CompletedMenopause Hot FlashesUnited States
-
University of California, San FranciscoCompleted
-
University of California, San FranciscoCompleted
-
AmgenCompleted
-
Alison Huang, MDNational Institute on Aging (NIA)Completed
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedTreatment of Menopausal Hot FlashesUnited States
-
Donesta BioscienceSynteractHCRCompleted
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)CompletedHot Flashes | Hot FlushesUnited States
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)CompletedFever, Sweats, and Hot FlashesUnited States
-
University of PennsylvaniaForest LaboratoriesCompleted
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States